Sugi Predict

Sugi Predict / Targets / NUP155

NUP155

Nuclear pore complex protein Nup155 · O75694 · NUP155 on Sugi Atlas →

1,871 patent compounds predicted against NUP155, 1,655 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Molibresib Molibresib (SCHEMBL1872390) 1.00 1/20
Molibresib Molibresib (SCHEMBL12671490) 1.00 1/20
Molibresib Molibresib (SCHEMBL12966358) 1.00 1/20
SCHEMBL9998851 SCHEMBL9998851 0.91 1/20
SCHEMBL14756282 SCHEMBL14756282 0.88 1/20
SCHEMBL15980874 SCHEMBL15980874 0.88 1/20
SCHEMBL12966165 SCHEMBL12966165 0.87 1/20
SCHEMBL14756215 SCHEMBL14756215 0.87 1/20
SCHEMBL14756339 SCHEMBL14756339 0.87 1/20
SCHEMBL15980861 SCHEMBL15980861 0.87 1/20
SCHEMBL9998825 SCHEMBL9998825 0.86 1/20
SCHEMBL15980893 SCHEMBL15980893 0.86 1/20
SCHEMBL15980803 SCHEMBL15980803 0.86 1/20
SCHEMBL1874116 SCHEMBL1874116 0.85 1/20
SCHEMBL12671221 SCHEMBL12671221 0.85 1/20
SCHEMBL14756021 SCHEMBL14756021 0.85 1/20
SCHEMBL14756240 SCHEMBL14756240 0.85 1/20
SCHEMBL14756287 SCHEMBL14756287 0.85 1/20
SCHEMBL14756335 SCHEMBL14756335 0.85 1/20
SCHEMBL14756409 SCHEMBL14756409 0.85 1/20

Clinical trials — most relevant to NUP155 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine PHASE1/PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) PHASE1/PHASE2COMPLETED
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia PHASE1COMPLETED
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma PHASE1WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) nanRECRUITING
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C nanRECRUITING
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） nanRECRUITING
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s) nanCOMPLETED
Biomarker for Niemann Pick Type C Disease (BioNPC) nanWITHDRAWN
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
Molecular Mechanism of Nasopharyngeal Carcinoma nanUNKNOWN
Azoospermia Patients nanRECRUITING
Family Study of Head and Neck Cancers in Taiwan nanCOMPLETED
Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging nanUNKNOWN
Comparative 2-D Tumor Analysis in Familial Gliomas nanCOMPLETED
Aberrant Gene Expression Prostate Carcinoma nanACTIVE_NOT_RECRUITING
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Identification of New FTLD Genes nanUNKNOWN
Molecular Markes of Fibrosis of Endometriosis and Their Use in Predicting Disease Severity nanRECRUITING
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia nanUNKNOWN
Autophagy/Apoptosis Balance in Placental Vascular Pathologies nanRECRUITING
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy nanCOMPLETED
Imaging Genetics of Laryngeal Dystonia nanRECRUITING
Primary Premature Ejaculation Genetics nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NUP155 binder may also engage these)

ProteinNameSimilarity
Q99P88 — 1.000 Q99P88 →
P37199 — 1.000 P37199 →
Q66HC5 — 0.989 Q66HC5 →
CPSF1 Cleavage and polyadenylation specificity factor subunit 1 0.985 landscape →
Q9H2M9 — 0.985 Q9H2M9 →
A5PJZ5 — 0.985 A5PJZ5 →
Q9ES00 — 0.984 Q9ES00 →
A0A0R4IC37 — 0.984 A0A0R4IC37 →
Q8BMG7 — 0.984 Q8BMG7 →
Q7ZX96 — 0.984 Q7ZX96 →
Q9EPU4 — 0.984 Q9EPU4 →
Q5U1Z0 — 0.983 Q5U1Z0 →
O94915 — 0.983 O94915 →
Q7ZU29 — 0.983 Q7ZU29 →
Q6P4S8 — 0.983 Q6P4S8 →
Q5R822 — 0.983 Q5R822 →
A2AF47 — 0.982 A2AF47 →
Q86UW7 — 0.982 Q86UW7 →
Q8CEC0 — 0.982 Q8CEC0 →
P21359 — 0.982 P21359 →
Q8BJ71 — 0.981 Q8BJ71 →
Q8WYP5 — 0.981 Q8WYP5 →
Q566H4 — 0.981 Q566H4 →
Q8N1I0 — 0.981 Q8N1I0 →
A2CEI4 — 0.981 A2CEI4 →
Q4QQS8 — 0.981 Q4QQS8 →
Q5ZL91 — 0.981 Q5ZL91 →
A1A4I9 — 0.980 A1A4I9 →
Q5SQE2 — 0.980 Q5SQE2 →
Q95JW3 — 0.980 Q95JW3 →